ConductScience.org, home

Paper25751499

Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.

Lussier DM and 9 others. J Immunother, 2015. Cited by 168 papers, by iCite.

Cite this record

ConductScience Library. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. Papers, record 25751499. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25751499

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
PubMed
Journal
J Immunother
PubMed
Year
2015
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
168
iCite
Relative citation ratio, by iCite
5.11
iCite
Revised in PubMed
2022-04-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lussier DMDanielle M
2O'Neill LLauren
3Nieves LMLizbeth M
4McAfee MSMegan S
5Holechek SASusan A
6Collins AWAndrea W
7Dickman PPaul
8Jacobsen JJeffrey
9Hingorani PPooja
10Blattman JNJoseph N

Source PubMed

Download CSV of authors

Topics25

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
B7-H1 AntigenMajor topic
Bone NeoplasmsMajor topic
ImmunomodulationMajor topic
OsteosarcomaMajor topic
Programmed Cell Death 1 ReceptorMajor topic
T-LymphocytesMajor topic
Adolescent
Adult
Animals
Cell Line, Tumor
Child
Cytokines
Cytotoxicity, Immunologic
Disease Models, Animal
Disease Progression
Gene Expression
Humans
Lymphocytes, Tumor-Infiltrating
Mice
Neoplasm Metastasis
Prognosis
T-Lymphocytes, Cytotoxic
Xenograft Model Antitumor Assays
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R25 GM071798NIGMS NIH HHSUnited StatesR25GM071798PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References56

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110561175Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.J Clin Oncol1999https://conductscience.org/library/papers/10561175PubMed
210850449Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas.Cancer Res2000https://conductscience.org/library/papers/10850449PubMed
312177108Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study.J Clin Oncol2002https://conductscience.org/library/papers/12177108PubMed
412209992Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.Int J Cancer2002https://conductscience.org/library/papers/12209992PubMed
512663797Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.J Virol2003https://conductscience.org/library/papers/12663797PubMed
612743156Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.J Clin Oncol2003https://conductscience.org/library/papers/12743156PubMed
715240681SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.J Immunol2004https://conductscience.org/library/papers/15240681PubMed
815705911Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.Cancer Res2005https://conductscience.org/library/papers/15705911PubMed
916458843Management of osteosarcoma pulmonary metastases.Semin Pediatr Surg2006https://conductscience.org/library/papers/16458843PubMed
1017363529PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.Clin Cancer Res2007https://conductscience.org/library/papers/17363529PubMed
1117404099Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.Clin Cancer Res2007https://conductscience.org/library/papers/17404099PubMed
1217646988Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.Cancer Immunol Immunother2008https://conductscience.org/library/papers/17646988PubMed
1317656078CD8 T cell dysfunction during chronic viral infection.Curr Opin Immunol2007https://conductscience.org/library/papers/17656078PubMed
1418613845Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections.Immunol Rev2008https://conductscience.org/library/papers/18613845PubMed
1518676751T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.Clin Cancer Res2008https://conductscience.org/library/papers/18676751PubMed
1618759925Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.Immunol Rev2008https://conductscience.org/library/papers/18759925PubMed
1719188168Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res2009https://conductscience.org/library/papers/19188168PubMed
1819695683Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.Hum Pathol2009https://conductscience.org/library/papers/19695683PubMed
1920143437Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.Cancer2010https://conductscience.org/library/papers/20143437PubMed
2020160101PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20160101PubMed

See all 56 referencesDownload CSV of references

Cited by124

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 168 citations.

PMIDTitleJournalYearIn PapersSource
42179886Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration.Regen Biomater2026https://conductscience.org/library/papers/42179886PubMed
41681090Immune Infiltration Landscape in Osteosarcoma: Clinical Implications for Prognosis and Therapy.Cancer Rep (Hoboken)2026https://conductscience.org/library/papers/41681090PubMed
41490859
Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study.
BMJ Open2026https://conductscience.org/library/papers/41490859PubMed
41209019Osteosarcoma immunometabolism: emerging mechanisms and clinical implications.Front Immunol2025https://conductscience.org/library/papers/41209019PubMed
40959529Molecular Impact of Magnesium-Mediated Immune Regulation in Diseases.Scientifica (Cairo)2025https://conductscience.org/library/papers/40959529PubMed
40941025The RNA-Binding Protein RBMX Mediates the Immunosuppressive Microenvironment of Osteosarcoma by Regulating CD8+T Cells.Cancers (Basel)2025https://conductscience.org/library/papers/40941025PubMed
40264674Synergistic chemo-immunotherapy for osteosarcoma via a pH-responsive multi-component nanoparticle system.Front Pharmacol2025https://conductscience.org/library/papers/40264674PubMed
40149640Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials.Biomedicines2025https://conductscience.org/library/papers/40149640PubMed
40119465Epigenetic regulators combined with tumour immunotherapy: current status and perspectives.Clin Epigenetics2025https://conductscience.org/library/papers/40119465PubMed
40099972Osteosarcoma Exosome Priming of Primary Human Lung Fibroblasts Induces an Immune Modulatory and Protumorigenic Phenotype.Cancer Res Commun2025https://conductscience.org/library/papers/40099972PubMed
39995821Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives.Front Immunol2024https://conductscience.org/library/papers/39995821PubMed
39916749Osteosarcoma: A comprehensive review of model systems and experimental therapies.Med Res Arch2024https://conductscience.org/library/papers/39916749PubMed
39811323T cell receptor signaling pathway subgroups and construction of a novel prognostic model in osteosarcoma.Heliyon2025https://conductscience.org/library/papers/39811323PubMed
39568569Primary osteosarcoma of the breast during lactation: a case report and literature review.Front Oncol2024https://conductscience.org/library/papers/39568569PubMed
39524888Prognostic signature and immunotherapeutic relevance of Focal adhesion signaling pathway-related genes in osteosarcoma.Heliyon2024https://conductscience.org/library/papers/39524888PubMed
39333065Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma.Bone Res2024https://conductscience.org/library/papers/39333065PubMed
39301541Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer.Front Oncol2024https://conductscience.org/library/papers/39301541PubMed
39273017PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients.Cells2024https://conductscience.org/library/papers/39273017PubMed
39245737Advances on immunotherapy for osteosarcoma.Mol Cancer2024https://conductscience.org/library/papers/39245737PubMed
38915446Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies.Front Cell Dev Biol2024https://conductscience.org/library/papers/38915446PubMed

See all 124 cited byDownload CSV of cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25751499

GET https://conductscience.org/api/papers/v1/25751499/references?page=2